ADC Conjugation Kit (Exatecan, DAR8, 1mg, for human IgG1)

Antibody-drug conjugates (ADCs) deliver potent cytotoxic drugs specifically to tumor cells, thereby enhancing antitumor efficacy and reducing the adverse systemic effects of the cytotoxic drugs. This kit is developed based on interchain cysteine conjugation technology: the interchain disulfide bonds of antibodies can be reduced to generate endogenous interchain cysteine residues, and payload drugs with maleimide functional groups can specifically conjugate to these cysteine residues to form structurally stable ADCs. Relying on this classic conjugation strategy, the kit enables a rapid and controllable ADC preparation process that takes only 3 hours in total; the prepared ADC products have an average drug-to-antibody ratio (DAR) of 8.0±0.5, and the ADC conjugates exhibit significant cytotoxic activity, providing a reliable experimental tool for ADC drug screening and mechanism research.

The ADC Conjugation Kit is designed to conjugate human IgG1 and cytotoxic payloads Exatecan through thiol and maleimide reaction chemistry. The ADC products can be used in cellular or animal experiments for the screening of suitable ADC candidates.

It is for research use only.

• Short Conjugation Time: Generates antibody-drug conjugates (ADCs) within 3 hours.
• Controllable DAR Value: Precisely regulates DAR while well preserving antibody activity.
• High Conjugation Efficiency & Recovery: Conjugation efficiency > 95%, antibody recovery rate > 80%.
• No Need for High-Concentration Antibodies: Reaction feasible with only 2 mg/mL of antibodies.
• Simple Purification: Purification completed in 15 minutes using spin desalting columns.

BoxA: This product remains stable when stored at -20℃ for 24 months.

BoxB: This product remains stable when stored at 2-8℃ for 24 months.

Please ensure use prior to the expiration date indicated on the packaging.